Biomica

Microbiome-based Therapeutics

Startup

Biomica is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2017. Microbiome-based Therapeutics. The company has raised a total of $37M across 2 funding rounds, currently at the A stage. Key investors include Shanghai Healthcare Capital, Evogene, Undisclosed Investor(s). The company has 11-50 employees. Core technologies: Artificial Intelligence, Biologicals, Molecules.

With $37M in total funding, Biomica is a A-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.

$37M
Raised
2
Rounds
3
Investors
3
Team
2017
Founded
1
Patents
Sector & Technology
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentArtificial IntelligenceBiologicalsMolecules
At a Glance
Investors
In the News

21 articles covered by sources including www.prnewswire.com, hitconsultant.net, www.benzinga.com, www.biospace.com, www.wflx.com.

www.prnewswire.com · May 23, 2024
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
Read article ↗
Frequently Asked Questions
What does Biomica do?

Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases, with specific focus on Immuno-Oncology and GI related disorders. The company aims to identify and target microbes, metabolites and other microbiome-related components that are key in the etiology of human diseases impacted by the microbiome, using both biological and small-molecule approaches. Biomica’s discovery and development efforts are powered by PRISM (Predictive, high Resolution, Integrative Selection of Microbes) platform. PRISM is a proprietary metagenomics analysis platform for functional genomics profiling utilizing internal comprehensive databases. Employing Biomica’s drug discovery approach, PRISM combines a profound understanding of the microbiome and its functions and their intricate relations with the human host. Biomica is a subsidiary of Evogene.

How much funding has Biomica raised?

Biomica has raised $37M in total funding across 2 rounds. The company is currently at the A stage. Key investors include Shanghai Healthcare Capital, Evogene, Undisclosed Investor(s).

What sector is Biomica in?

Biomica operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Artificial Intelligence, Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology.

Where is Biomica located?

Biomica is based in Derech Gad Feinstein 13, Rehovot, Israel, Center District.

View Full Profile Classic View Website ↗